TrialBritish journal of clinical pharmacology2022

Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.

Ronald de Wit et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.